Business
Award of Grant
Award of Grant.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 5302H Physiomics PLC 20 June 2013 \n \n\n \n \nPhysiomics plc\nThe Magdalen Centre\nThe Oxford Science Park\nRobert Robinson Avenue\nOxford\nOX4 4GA\nUK\n \nTel 01865 784980\nFax 08701 671931\n20 June 2013 \nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics awarded a Biomedical Catalyst GRANT from the UK Technology Strategy Board\n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been awarded a GBP148,465 grant from the UK's innovation agency, the Technology Strategy Board's Biomedical Catalyst fund. The grant will provide additional support for the development of the Company's flagship Virtual Tumour Clinical platform. \n \nThe Company's existing Virtual Tumour platform is used to optimise drug dosing and scheduling in pre-clinical experiments. This helps customers to save time and money, and also helps them improve drug potency. The new Clinical version of Virtual Tumour under development will be designed to optimise dosing and scheduling in human patients.\n \n \nMore information about the clinical virtual tumour technology may be found on Physiomics website at:\nhttp://www.physiomics-plc.com/services/virtual-tumour-clinical/\n \nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are very pleased to be awarded this prestigious grant. Physiomics has received strong feedback from the majority of existing and potential customers that extending the Virtual Tumour technology into the clinic would be very desirable for them. We look forward to engaging with a large pharma partner in the near future to further accelerate the new platform\"\n \n \n \nEnquiries:\n \nPhysiomics plc \nDr Mark Chadwick, CEO\n+44 (0)1865 784 980\n \n \nWH Ireland Limited (broker/nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \n \nAbout Physiom...